These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27608722)

  • 1. End-point indicators of low-dose intra-tympanic gentamicin in management of Ménière's disease.
    Liu H; Zhang T; Wu Q; Zhang Y; Dai C
    Acta Otolaryngol; 2017 Feb; 137(2):136-143. PubMed ID: 27608722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratympanic gentamicin injection for refractory ménière's disease (MD) has potential effect in preventing contralateral MD occurrence.
    Wu Y; Zhou Y; Yu J; Song Z; Dai C; Wang J
    Acta Otolaryngol; 2021 Jul; 141(7):657-662. PubMed ID: 33950779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of intractable Ménière's disease after intratympanic injection of gentamicin.
    Rah YC; Han JJ; Park J; Choi BY; Koo JW
    Laryngoscope; 2015 Apr; 125(4):972-8. PubMed ID: 25363447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliability of the vestibular evoked myogenic potential test in assessing intratympanic gentamicin therapy in Meniere's disease.
    Ozluoglu LN; Akkuzu G; Ozgirgin N; Tarhan E
    Acta Otolaryngol; 2008 Apr; 128(4):422-6. PubMed ID: 18368577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-shot, low-dose intratympanic gentamicin in Ménière disease: role of vestibular-evoked myogenic potentials and caloric test in the prediction of outcome.
    Gode S; Celebisoy N; Akyuz A; Gulec F; Karapolat H; Bilgen C; Kirazli T
    Am J Otolaryngol; 2011; 32(5):412-6. PubMed ID: 20851502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change of VOR gain and pure-tone threshold after single low-dose intratympanic gentamicin injection in Meniere's disease.
    Lee JY; Kim MB
    Acta Otolaryngol; 2020 Apr; 140(4):314-318. PubMed ID: 31909683
    [No Abstract]   [Full Text] [Related]  

  • 7. Cochlear function in Ménière's disease.
    Büki B; Jünger H; Avan P
    Int J Audiol; 2012 May; 51(5):373-8. PubMed ID: 22283464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEMPs and dynamic posturography after intratympanic gentamycin in Menière's disease.
    Picciotti PM; Fiorita A; Di Nardo W; Quaranta N; Paludetti G; Maurizi M
    J Vestib Res; 2005; 15(3):161-8. PubMed ID: 16179764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term hearing outcome in patients receiving intratympanic gentamicin for Ménière's disease.
    Wu IC; Minor LB
    Laryngoscope; 2003 May; 113(5):815-20. PubMed ID: 12792316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractory episodic vertigo: role of intratympanic gentamicin and vestibular evoked myogenic potentials.
    Celis-Aguilar E; Hinojosa-González R; Vales-Hidalgo O; Coutinho-Toledo H
    Braz J Otorhinolaryngol; 2016; 82(6):668-673. PubMed ID: 27068887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose intratympanic gentamicin instillations for treatment of Meniere's disease: long-term results.
    Hsieh LC; Lin HC; Tsai HT; Ko YC; Shu MT; Lin LH
    Acta Otolaryngol; 2009 Dec; 129(12):1420-4. PubMed ID: 19922092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratympanic gentamicin for intractable Meniere's disease.
    Perez N; Martín E; García-Tapia R
    Laryngoscope; 2003 Mar; 113(3):456-64. PubMed ID: 12616197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified titration intratympanic gentamicin injection for unilateral intractable Ménière's disease.
    Liu B; Leng YM; Shi H; Zhou RH; Liu JJ; Zhang WJ; Zhang SL; Kong WJ
    J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):747-751. PubMed ID: 26489633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Instrumental head impulse test changes after intratympanic gentamicin for unilateral definite Ménière's disease: A systematic review and meta-analysis.
    Marques PS; Dias CC; Perez-Fernandez N; Spratley J
    Auris Nasus Larynx; 2018 Oct; 45(5):943-951. PubMed ID: 29402608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of endolymphatic shunt surgery and intratympanic gentamicin for meniere's disease.
    Gibson AW; Moon IJ; Golub JS; Rubinstein JT
    Laryngoscope; 2020 Oct; 130(10):2455-2460. PubMed ID: 31808957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Ménière's disease by low-dosage intratympanic gentamicin application: effect on otolith function.
    Helling K; Schönfeld U; Clarke AH
    Laryngoscope; 2007 Dec; 117(12):2244-50. PubMed ID: 17909448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratympanic gentamicin for control of vertigo in Meniere's disease: vestibular signs that specify completion of therapy.
    Minor LB
    Am J Otol; 1999 Mar; 20(2):209-19. PubMed ID: 10100525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratympanic gentamicin treatment of patients with Ménière's disease with normal hearing.
    Silverstein H; Wazen J; Van Ess MJ; Daugherty J; Alameda YA
    Otolaryngol Head Neck Surg; 2010 Apr; 142(4):570-5. PubMed ID: 20304280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratympanic gentamicin injections for the treatment of Ménière's disease.
    Katzenell U; Gordon M; Page M
    Otolaryngol Head Neck Surg; 2010 Nov; 143(5 Suppl 3):S24-9. PubMed ID: 20970688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single intratympanic gentamicin injection in Ménière's disease: VOR change and prognostic usefulness.
    Marques P; Manrique-Huarte R; Perez-Fernandez N
    Laryngoscope; 2015 Aug; 125(8):1915-20. PubMed ID: 25641686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.